Minor grove binding ligands disrupt PARP-1 activation pathways

К. I. Kirsanov, Elena Kotova, Petr Makhov, Konstantin Golovine, Ekaterina A. Lesovaya, Vladimir Kolenko, Marianna G. Yakubovskaya, Alexei V. Tulin

Oncotarget · 2014 · 28 citations · 31 references

DOIFull text

Open access

Concepts

Abstract

// Kirill I. Kirsanov 1,* , Elena Kotova 2,* , Petr Makhov 2 , Konstantin Golovine 2 , Ekaterina A. Lesovaya 1 , Vladimir M. Kolenko 2 , Marianna G. Yakubovskaya 1 , Alexei V. Tulin 2 1 Blokhin Cancer Research Center RAMS, Moscow, Russia 2 Fox Chase Cancer Center, Philadelphia, PA * These authors contributed equally to this work Correspondence: Alexei V. Tulin, email: // Keywords : PARP-1, PARP-1 inhibitors, DNA-binding small molecules, poly(ADP-ribose) Received : December 25, 2013 Accepted : January 3, 2014 Published : January 3, 2014 Abstract PARP-1 is a nuclear enzyme regulating transcription, chromatin restructuring, and DNA repair. PARP-1 is activated by interaction with NAD+, DNA, and core histones. Each route of PARP-1 activation leads to somewhat different outcomes. PARP-1 interactions with core histones control PARP-1 functions during transcriptional activation in euchromatin. DNA-dependent regulation of PARP-1 determines its localization in heterochromatin and PARP-1-dependent silencing. Here we address the biological significance of DNA-dependent PARP-1 regulation in vitro and in vivo . We report that minor grove binding ligands (MGBLs) specifically target PARP-1 interaction with DNA, and, hence, the DNA-dependent pathway of PARP-1 activation. By obstructing its interaction with DNA molecules, MGBLs block PARP-1 activity in vitro and in vivo , as we demonstrate using Drosophila , as well as human cancer-derived cells. We also demonstrate synergistic inhibition of PARP-1, combining MGBLs with conventional NAD+-dependent inhibitors in human cancer cells. These results suggest that combining different classes of PARP-1 inhibitors can precisely modulate PARP-1 activity in living cells, thus holding promise for new avenues of cancer treatment.

References

31